Biote Corp. (BTMD) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.94 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 360%. A quarter ago, it was expected that this company would post earnings of $0.08 per share when it actually produced earnings of $0.14, delivering a surprise of 75%.Over the last four quarters, the company has surpa ...

Procedure revenue growth and strengthened profitability drive solid financial performance IRVING, TX – May 7, 2024—Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024. • Revenue of $46.8 million, up 4.4% "Procedure revenue increased 6.6% in the first quarter, reflecting stable demand from established clinics within our natio ...

The market expects biote Corp. (BTMD) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 7, 2024, might help the stock move higher if these key numbers are bette ...

The information required by this item is incorporated by reference to the information set forth in the sections titled "Proposal 1 —Election of Directors," "Information Regarding the Board of Directors and Corporate Governance," and "Information Regarding Executive Officers," which will be included in our definitive proxy statement for our 2024 Annual Meeting of Shareholders (the "2024 Proxy Statement"), if the 2024 Proxy Statement is filed with the SEC within 120 days after December 31, 2023, or will other ...

biote Corp. (OTCPK:FSNUF) Q4 2023 Earnings Conference Call March 12, 2024 5:00 PM ET Company Participants Marc Beer - Executive Chairman Dr. Ross McQuivey - Chief Medical Officer Richard Magnusen - B. Riley & Co. Kaumil Gajrawala - Jefferies Operator Simon Serowiecki Thank you for joining us today. This evening, biote published financial results for the quarter and full year ended December 31, 2023. This news release is available on the Investor Relations section of the company's website. Terry Weber, Chief ...

The market expects biote Corp. (BTMD) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with Dr. Gary S. Donovitz (“Donovitz”), founder and stockholder of Biote, to resolve outstanding litigation. In connection with this agreement, Biote will repurchase all of the Class A common units of Biote Holdings, LLC (“Holdings Uni ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved a $20 million share repurchase program of the Company's common stock. This approval grants Biote’s management the authority to repurchase outstanding shares of the Company’s common stock, from time to time, in the open market, in ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and Adjusted EBITDA to be slightly below prior guidance. The Company had previously forecast that revenue and Adjusted EBITDA would be toward the lower end of the previously announced ranges of $190-$200 million and $56-$60 million, ...

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-c ...